Skip to main content

Balaji Prasad

Stock Analyst at Barclays

Total Price Targets
11
Stocks Covered
7
Sectors
Healthcare
Most Recent
Feb 27, 2025

Stocks Covered by Balaji Prasad

SymbolCompanyLatest TargetCurrent PriceUpside# TargetsLast Updated
JAZZJazz Pharmaceuticals plc$200.00$202.38-1.2%2Feb 27, 2025
TARSTarsus Pharmaceuticals, Inc.$62.00$63.56-2.5%1Jan 27, 2025
ELANElanco Animal Health Incorporated$22.00$22.52-2.3%1Sep 23, 2024
EOLSEvolus, Inc.$20.00$5.29+278.4%2Sep 13, 2024
ZTSZoetis Inc.$242.00$114.14+112.0%1Aug 7, 2024
ALVOAlvotech$22.00$3.46+534.9%3May 24, 2024
IDXXIDEXX Laboratories, Inc.$700.00$568.78+23.1%1May 6, 2022

Recent Activity

  • Feb 27, 2025— Set$200.00price target onJAZZ(Jazz Pharmaceuticals plc)
  • Jan 27, 2025— Set$62.00price target onTARS(Tarsus Pharmaceuticals, Inc.)
  • Sep 23, 2024— Set$22.00price target onELAN(Elanco Animal Health Incorporated)
  • Sep 13, 2024— Set$20.00price target onEOLS(Evolus, Inc.)
  • Aug 7, 2024— Set$242.00price target onZTS(Zoetis Inc.)
  • May 24, 2024— Set$22.00price target onALVO(Alvotech)
  • May 21, 2024— Set$20.00price target onALVO(Alvotech)
  • Jan 29, 2024— Set$16.00price target onEOLS(Evolus, Inc.)
  • Jan 29, 2024— Set$17.00price target onALVO(Alvotech)
  • May 6, 2022— Set$700.00price target onIDXX(IDEXX Laboratories, Inc.)
  • Jun 22, 2021— Set$250.00price target onJAZZ(Jazz Pharmaceuticals plc)

Frequently Asked Questions

Who is Balaji Prasad?

Balaji Prasad is a stock analyst at Barclays covering 7 stocks primarily in Healthcare. They have issued 11 price targets since Jun 22, 2021.

What stocks does Balaji Prasad cover?

Balaji Prasad currently covers 7 stocks, including ALVO, JAZZ, EOLS, TARS, ELAN.

What is Balaji Prasad's latest price target?

Balaji Prasad's most recent price target was $200.00 on JAZZ (Jazz Pharmaceuticals plc), set on Feb 27, 2025.

What is Balaji Prasad's highest price target?

Balaji Prasad's highest issued price target is $700.00 on IDXX, set on May 6, 2022.

Coverage based on publicly published price targets. Not investment advice.